← United States · Coverage record
US · SEC FORM 4
Biomea Fusion, Inc.
BMEA · Nasdaq · CIK 0001840439 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-12-11 · Erdtmann Rainer M.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -54.3%
- 3M
- -37.2%
- 6M
- -59.2%
- 12M
- -47.5%
Volatility & liquidity
- Volatility
- 105.2%
- Beta
- —
- Avg daily value
- USD 1.7M
Valuation
- Market cap
- USD 60.6M
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- -209.1%
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-19 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 14,077,283
- Previous report
- 13,220,480
- Avg daily volume
- 2,490,242
- Days to cover
- 5.7
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | Erdtmann Rainer M | Purchase (P) | Common Stock | 30,000 | USD 1.43 | USD 42,900 | SEC filing ↗ |
| 2025-12-02 | Hitchcock Michael J.M. | Purchase (P) | Common Stock | 100,000 | USD 0.99 | USD 99,000 | SEC filing ↗ |
| 2025-12-01 | Erdtmann Rainer M | Purchase (P) | Common Stock | 10,000 | USD 1.05 | USD 10,500 | SEC filing ↗ |
| 2025-11-28 | Erdtmann Rainer M | Purchase (P) | Common Stock | 40,000 | USD 1.10 | USD 44,000 | SEC filing ↗ |
| 2024-09-30 | Hitchcock Michael J.M. | Purchase (P) | Common Stock | 10,000 | USD 10.06 | USD 100,600 | SEC filing ↗ |
| 2024-06-11 | Valle Franco | Purchase (P) | Common Stock | 12,509 | USD 4.43 | USD 55,415 | SEC filing ↗ |
| 2023-03-30 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund III LP | Purchase (P) | Common Stock | 400,000 | USD 30.00 | USD 12,000,000 | SEC filing ↗ |
| 2022-11-14 | Hitchcock Michael J.M. | Purchase (P) | Common Stock | 5,000 | USD 7.93 | USD 39,650 | SEC filing ↗ |
| 2022-11-11 | Valle Franco | Purchase (P) | Common Stock | 4,100 | USD 7.63 | USD 31,283 | SEC filing ↗ |
| 2022-08-16 | A2A Pharmaceuticals, Inc. | Purchase (P) | Common Stock | 30,684 | USD 13.87 | USD 425,587 | SEC filing ↗ |
| 2022-01-14 | Valle Franco | Purchase (P) | Common Stock | 10,000 | USD 8.68 | USD 86,800 | SEC filing ↗ |
| 2021-09-17 | Stergiopoulos Sotirios | Purchase (P) | Common Stock | 34,658 | USD 10.96 | USD 379,852 | SEC filing ↗ |
| 2021-09-17 | A2A Pharmaceuticals, Inc. | Purchase (P) | Common Stock | 34,658 | USD 10.96 | USD 379,852 | SEC filing ↗ |
| 2021-08-23 | Erdtmann Rainer M | Purchase (P) | Common Stock | 24,000 | USD 13.20 | USD 316,800 | SEC filing ↗ |
| 2021-08-23 | Butler Thomas Andrew | Purchase (P) | Common Stock | 24,000 | USD 13.20 | USD 316,800 | SEC filing ↗ |
Form 4 evidence
6 transaction lines in the latest 365-day window; 54 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Erdtmann Rainer M | Gift (G) | Common Stock | 100,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-11 | Erdtmann Rainer M | Purchase (P) | Common Stock | 30,000 | USD 1.43 | USD 42,900 | SEC filing ↗ |
| 2025-12-02 | Hitchcock Michael J.M. | Purchase (P) | Common Stock | 100,000 | USD 0.99 | USD 99,000 | SEC filing ↗ |
Show recent Form 4 evidence (5 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Erdtmann Rainer M | Gift (G) | Common Stock | 100,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-11 | Erdtmann Rainer M | Purchase (P) | Common Stock | 30,000 | USD 1.43 | USD 42,900 | SEC filing ↗ |
| 2025-12-02 | Hitchcock Michael J.M. | Purchase (P) | Common Stock | 100,000 | USD 0.99 | USD 99,000 | SEC filing ↗ |
| 2025-12-01 | Erdtmann Rainer M | Purchase (P) | Common Stock | 10,000 | USD 1.05 | USD 10,500 | SEC filing ↗ |
| 2025-11-28 | Erdtmann Rainer M | Purchase (P) | Common Stock | 40,000 | USD 1.10 | USD 44,000 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | BMEA |
| CIK | 0001840439 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 54 transaction lines from 2021-04-15 to 2025-12-31 24 P purchase lines · 10 S sale lines · 20 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.